What CD4 T-cell count initiates medication for HIV-positive patients according to current guidelines?

Initiation of antiretroviral therapy (ART) for HIV-positive patients is generally guided by CD4 T-cell count. According to current guidelines, a CD4 T-cell count of less than 350 cells/mm3 is a critical threshold where initiation of HIV medication is recommended, as this level indicates significant immunosuppression and an increased risk of opportunistic infections.

At this count, the immune system is already compromised, and there's a substantial benefit to starting therapy not only to improve the patient's health and survival but also to reduce the risk of transmitting the virus to others. The recommendations may vary slightly across different organizations, but a CD4 count lower than 350 is commonly recognized as a key point for beginning treatment, reflecting the need to intervene before the immune system deteriorates further.

Higher counts, such as those indicated in the other choices, represent a less urgent need for initiation of therapy, given that patients with higher CD4 T-cell levels typically retain a stronger immune response and are at a reduced risk of complications associated with HIV. However, current guidelines favor starting treatment at the lower threshold to enhance long-term health outcomes for the patient.